Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Leader trust behaviours as predictors of functional outcomes in infantry soldiers.

Occupational medicine (Oxford, England)·2026
Same author

Liver transplantation in unresectable intrahepatic cholangiocarcinoma following neoadjuvant chemotherapy and SIRT.

JHEP reports : innovation in hepatology·2026
Same author

Health-related quality of life in biliary tract cancer clinical trials. The current state and future directions.

ESMO gastrointestinal oncology·2026
Same author

Corrigendum to "Current and investigational medications for the treatment of sarcopenia" [Metabolism 2023;149:155597].

Metabolism: clinical and experimental·2026
Same author

Reply to letter comments on: Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine).

ESMO open·2025
Same author

Drying Spring Accelerates Transitions Toward Pyrogenic Vegetation in Eastern Boreal North America.

Ecology letters·2025

Related Experiment Video

Updated: Jun 5, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

[Radioembolisation for hepatocellular carcinoma].

J-L Raoul1, J Edeline, M Pracht

  • 1Département d'oncologie médicale, centre Eugène-Marquis, rue de la bataille Flandres-Dunkerque, Rennes cedex, France. raoul@rennes.fnclcc.fr

Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|January 18, 2011
PubMed
Summary

Hepatocellular carcinoma (HCC) treatment faces challenges. Radioembolization offers a promising alternative to chemoembolization for intermediate-stage HCC, with microspheres showing potential for future advancements.

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Related Experiment Videos

Last Updated: Jun 5, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Area of Science:

  • Hepatocellular carcinoma (HCC) research
  • Interventional oncology
  • Radiopharmaceuticals

Context:

  • HCC is a significant public health issue.
  • Intermediate-stage HCC patients often receive chemoembolization, which has limitations.
  • Current chemoembolization techniques for HCC show moderate efficacy and poor tolerance.

Purpose:

  • To evaluate radioembolization as an alternative treatment for intermediate-stage HCC.
  • To discuss current radioembolization agents and their efficacy.
  • To explore future directions for HCC treatment, including combination therapies.

Summary:

  • Radioembolization is presented as a potential superior treatment for intermediate-stage hepatocellular carcinoma compared to chemoembolization.
  • Available radioembolization agents include (131)I-Lipiodol, (188)Re-Lipiodol, and (90)Y-based microspheres.
  • Promising data exist for microsphere-based radioembolization, though further Phase II and III studies are required.

Impact:

  • Radioembolization could improve outcomes for intermediate-stage HCC patients.
  • Future research should focus on microsphere efficacy and combination therapies.
  • Combining radioembolization with chemotherapy or antiangiogenic drugs may enhance HCC treatment effectiveness.